Regístrese
Buscar en
Revista Colombiana de Cancerología
Toda la web
Inicio Revista Colombiana de Cancerología Neoadyuvancia en cáncer de mama
Información de la revista
Vol. 13. Núm. 3.
Páginas 157-174 (Enero 2009)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 13. Núm. 3.
Páginas 157-174 (Enero 2009)
DOI: 10.1016/S0123-9015(09)70134-9
Acceso a texto completo
Neoadyuvancia en cáncer de mama
Neoadjuvant Therapy in Breast Cancer
Visitas
5599
Ricardo Brugés1,
Autor para correspondencia
ricardobruges@gmail.com

Correspondencia: Ricardo Brugés. Instituto Nacional de Cancerología. Av. 1a No. 9-85. Tel.: (571) 334 1111. Bogotá, Colombia.
, Luis Hernán Guzmán1, Oswaldo Sánchez1,2, Sandra Díaz1, Édgar Vergara1
1 Instituto Nacional de Cancerología. Bogotá, Colombia
2 Hospital San Ignacio. Bogotá, Colombia
Este artículo ha recibido
5599
Visitas
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

El tratamiento neoadyuvante —también denominado “terapia primaria sistémica” o “terapia preoperatoria”— tiene cuatro finalidades en cáncer de mama: disminuir el volumen tumoral para hacer operable lo que antes era inoperable, mejorar las probabilidades para hacer una cirugía conservativa, analizar la quimiosensibilidad in vivo y evaluar el manejo de las micrometástasis. Esta revisión descriptiva toma en cuenta los principales estudios clínicos sobre terapia sistémica neoadyuvante publicados hasta mayo del 2009.

Palabras clave:
neoplasias de la mama
terapia neoadyuvante
protocolos antineoplásicos
trastuzumab
lapatinib
bevacizumab
tamoxifeno
tasas de supervivencia
supervivencia libre de enfermedad.
Abstract

Neoadjuvant treatment —also known as primary systemic therapy or preoperative therapy— has four objectives when applied to breast cancer: to reduce inoperable tumoral volume to operable size; to enhance the possiblility for conservative surgery; to analyze chemosensitivity in vivo; and, to evaluate the management of micrometastasis. This descriptive review takes into account the major clinical studies on systemic neoadjuvant therapy published as of May, 2009.

Key words:
Breast neoplasm
neoadjuvant therapy
antineoplastic protocols
trastuzumab
lapatinib
bevacizumab
tamoxifen
survival rate
disease free survival.
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Kaufmann, G. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, et al.
Recommendations from an International Expert Panel on the use of neoadjuvant (Primary) systemic treatment of operable breast cancer: an update.
J Clin Oncol, 24 (2006), pp. 1940-1949
[2.]
República de Colombia; Ministerio de la Protección Social; Instituto Nacional de Cancerología.
Anuario estadístico 2007.
Legis, (2008),
[3.]
H. Charfare, S. Limongelli, A.D. Purushotham.
Neoadjuvant chemotherapy in breast cancer.
Br J Surg, 92 (2005), pp. 14-23
[4.]
D. Bafaloukos.
Neo-adjuvant therapy in breast cancer.
Ann Oncol, 16 (2005),
[5.]
J.A. van der Hage, C.J. van de Velde, J.P. Julien, M. Tubiana-Hulin, C. Vandervelden, L. Duchateau.
Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.
J Clin Oncol, 19 (2001), pp. 4224-4237
[6.]
B. Fisher, J. Bryant, N. Wolmark, E. Mamounas, A. Brown, E.R. Fisher, et al.
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
J Clin Oncol, 16 (1998), pp. 2672-2685
[7.]
B. Chevallier, H. Roche, J.P. Olivier, P. Chollet, P. Hurteloup.
Inflammatory breast cancer: Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histology response rate.
Am J Clin Oncol, 16 (1993), pp. 223-228
[8.]
H.P. Sinn, H. Schmid, H. Junkermann, J. Huober, G. Leppien, M. Kaufmann, et al.
Histologische regression des mammakarzinoms nach primarer (neoadjuvanter) Chemotherapie.
Geburtsh Frauenheilk, 54 (1994), pp. 552-558
[9.]
D.M. Sataloff, B.A. Mason, A.J. Prestipino, U.L. Seinige, C.P. Lieber, Z. Baloch.
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome.
J Am Coll Surg, 180 (1995), pp. 297-306
[10.]
A.H. Honkoop, P.J. van Diest, J.S. de Jong, S.C. Linn, G. Giaccone, K. Hoekman, et al.
Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.
Br J Cancer, 77 (1998), pp. 621-626
[11.]
H.M. Kuerer, L.A. Newman, T.M. Smith, F.C. Ames, K.K. Hunt, K. Dhingra, et al.
Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.
J Clin Oncol, 17 (1999), pp. 460-469
[12.]
J.Y. Pierga, E. Mouret, V. Dieras, V. Laurence, P. Beuzeboc, T. Dorval, et al.
Prognostic value of persistent node involvement after neo adjuvant chemotherapy in patients with operable breast cancer.
Br J Cancer, 83 (2000), pp. 1480-1487
[13.]
K.N. Ogston, I.D. Miller, S. Payne, A.W. Hutcheon, T.K. Sarkar, I. Smith, et al.
A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival.
Breast, 12 (2003), pp. 320-327
[14.]
A.B. Miller, B. Hoogstraten, M. Staquet, A. Winkler.
Reporting results of cancer treatment.
Cancer, 47 (1981), pp. 207-214
[15.]
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, et al.
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).
Eur J Cancer, 45 (2009), pp. 228-247
[16.]
G. Bonadonna, U. Veronesi, C. Brambilla, L. Ferrari, A. Luini, M. Greco, et al.
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.
J Natl Cancer Inst, 82 (1990), pp. 1539-1545
[17.]
G. Gardin, R. Rosso, E. Campora, L. Repetto, C. Naso, G. Canavese, et al.
Locally advanced non-metastatic breast cancer: Analysis of prognostic factors in 125 patients homogenously treated with a combined modality approach.
Eur J Cancer, 31A (1995), pp. 1428-1433
[18.]
I.E. Smith, G. Walsh, A. Jones, J. Prendiville, S. Johnston, B. Gusterson, et al.
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer.
J Clin Oncol, 13 (1995), pp. 424-429
[19.]
P. Chollet, S. Charier, E. Brain, H. Curé, I. van Praagh, V. Feillel, et al.
Clinical and pathological response to primary chemotherapy in operable breast cancer.
Eur J Cancer, 33 (1997), pp. 862-866
[20.]
C. Jacquillat, M. Weil, F. Baillet, C. Borel, G. Auclerc, M. de Maublanc, et al.
Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer.
Cancer, 66 (1990), pp. 119-129
[21.]
S. Amat, P. Bougnoux, F. Penault-Llorca, F. Fetissof, H. Curé, F. Kwiatkowski, et al.
Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breastconservation rate.
Br J Cancer, 88 (2003), pp. 1339-1345
[22.]
E. Belembaogo, V. Feillel, P. Chollet, H. Curé, P. Verrelle, F. Kwiatskowski, et al.
Neoadjuvant chemotherapy in 126 operable breast cancers.
Eur J Cancer, 28A (1992), pp. 896-900
[23.]
G.F. Schwartz, R.I. Cantor, W.A. Biermann.
Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast.
Arch Surg, 122 (1987), pp. 1430-1434
[24.]
J.S.D. Mieog, J.A. van der Hage, C.J.H. van de Velde.
Preoperative chemotherapy for women with operable breast cancer.
Cochrane Database Syst Rev, 18 (2007), pp. CD005002
[25.]
D. Mauri, N. Pavlidis, J.P. Ioannidis.
Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis.
J Natl Cancer Inst, 97 (2005), pp. 188-194
[26.]
V.F. Semiglazov, E.E. Topuzov, J.L. Bavli, V.M. Moiseyenko, O.A. Ivanova, I.K. Seleznev, et al.
Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.
Ann Oncol, 5 (1994), pp. 591-595
[27.]
L. Mauriac, M. Durand, A. Avril, J.M. Dilhuydy.
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm Results of a randomized trial in a single centre.
Ann Oncol, 2 (1991), pp. 347-354
[28.]
L. Mauriac, G. MacGrogan, A. Avril, M. Durand, A. Floquet, M. Debled, et al.
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up Institut Bergonie Bordeaux Groupe Sein (IBBGS).
Ann Oncol, 10 (1999), pp. 47-52
[29.]
S.M. Scholl, A. Fourquet, B. Asselain, J.Y. Pierga, J.R. Vilcoq, J.C. Durand, et al.
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.
Eur J Cancer, 30A (1994), pp. 645-652
[30.]
S.M. Scholl, J.Y. Pierga, B. Asselain, P. Beuzeboc, T. Dorval, E. Garcia-Giralt, et al.
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.
Eur J Cancer, 31A (1995), pp. 1969-1975
[31.]
S.M. Scholl, B. Asselain, T. Palangie, T. Dorval, M. Jouve, E. GarciaGiral, et al.
Neoadjuvant chemotherapy in operable breast cancer.
Eur J Cancer, 27 (1991), pp. 1668-1671
[32.]
T.J. Powles, T.F. Hickish, A. Makris, S.E. Ashley, M.E. O’Brien, V.A. Tidy, et al.
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.
J Clin Oncol, 13 (1995), pp. 547-552
[33.]
N. Wolmark, J. Wang, E. Mamounas, J. Bryant, B. Fisher.
Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.
J Natl Cancer Inst Monogr, (2001), pp. 96-102
[34.]
A. Avril, A. Faucher, E. Bussières, E. Stöckle, M. Durand, L. Mauriac, et al.
Results of 10 years of a randomized trial of neoadjuvant chemotherapy in breast cancers larger than 3cm.
Chirurgie, 123 (1998), pp. 247-256
[35.]
S.J. Cleator, A. Makris, S.E. Ashley, R. Lal, T.J. Powles.
Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival.
Ann Oncol, 16 (2005), pp. 267-272
[36.]
A. Makris, T.J. Powles, S.E. Ashley, J. Chang, T. Hickish, V.A. Tidy, et al.
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer.
Ann Oncol, 9 (1998), pp. 1179-1184
[37.]
J.C. Gazet, H.T. Ford, R. Gray, C. McConkey, R. Sutcliffe, J. Quilliam, et al.
Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy.
Ann Oncol, 12 (2001), pp. 685-691
[38.]
D.N. Danforth Jr., K. Cowan, R. Altemus, M. Merino, C. Chow, A. Berman, et al.
Preoperative FLAC/granulocytecolony-stimulating factor chemotherapy for stage II breast cancer: a prospective randomized trial.
Ann Surg Oncol, 10 (2003), pp. 635-644
[39.]
S.V. Deo, M. Bhutani, N.K. Shukla, V. Raina, G.K. Rath, J. Purkayasth.
Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0).
J Surg Oncol, 84 (2003), pp. 192-197
[40.]
P. Forouhi, J.M. Dixon, R.C. Leonard, U. Chetty.
Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer.
Br J Surg, 82 (1995), pp. 79-82
[41.]
K. Enomoto, T. Ikeda, A. Matsui, M. Kitajima, J. Koh, S. Masamura, et al.
Neoadjuvant therapy in stage IIwith Toe=4CMand stage III breast cancer.
6th International Conference Adjuvant therapy for Primary Breast Cancer St Gallen, pp. P73
[42.]
G. Bulotiene, J. Veseliunas, V. Ostapenko.
Quality of life of Lithuanian women with early stage breast cancer.
BMC Public Health, 26 (2007), pp. 7-124
[43.]
A.U. Buzdar, S.E. Singletary, R.L. Theriault, D.J. Booser, V. Valero, N. Ibrahim, et al.
Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer.
J Clin Oncol, 17 (1999), pp. 3412-3417
[44.]
H.D. Bear, S. Anderson, R.E. Smith, et al.
A randomized trial comparing preoperative doxorubicin/cyclophosphamide (AC) to preoperative AC followed by preoperat ive docetaxel (T) and to preoperative AC fol lowed by postoperative T in patients with operable carcinoma of the breast: results of NSABP B-27.
San Antonio Breast Cancer Symposium 2004,
[45.]
H.D. Bear, S. Anderson, R.E. Smith, C.E. Geyer, E.P. Mamounas, B. Fisher, et al.
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27.
J Clin Oncol, 24 (2006), pp. 2019-2027
[46.]
T.R. Evans, A. Yellowlees, E. Foster, H. Earl, D.A. Cameron, A.W. Hutcheon, et al.
Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group Study.
J Clin Oncol, 23 (2005), pp. 2988-2995
[47.]
G. von Minckwitz, G. Raab, A. Caputo, M. Schütte, J. Hilfrich, J.U. Blohmer, et al.
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
J Clin Oncol, 23 (2005), pp. 2676-2685
[48.]
M. Untch, G. Konecny, N. Ditsch, et al.
Dose-dense sequential epirubicin paclitaxel as preoperative treatment of breast cancer: results of a randomized AGO study.
Proc Am Soc Clin Oncol, 21 (2002), pp. 133a
[49.]
I. Sachelarie, M.L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, R. Blum.
Primary systemic therapy of breast cancer.
Oncologist, 11 (2006), pp. 574-589
[50.]
M.C. Green, A.U. Buzdar, T. Smith, N.K. Ibrahim, V. Valero, M.F. Rosales, et al.
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.
J Clin Oncol, 23 (2005), pp. 5983-5992
[51.]
I.C. Henderson, D.A. Berry, G.D. Demetri, C.T. Cirrincione, L.J. Goldstein, S. Martino, et al.
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen forpatients with node-positive primary breast cancer.
J Clin Oncol, 21 (2003), pp. 976-983
[52.]
M. Trudeau, S. Sinclair, M. Clemons, W. Shelley.
Breast Cancer Disease Site Group The role of taxanes in neoadjuvant chemotherapy for women with non-metastatic breast cancer Practice Guideline Report #1-20.
Cancer Care Ontario, (2004),
[53.]
S. Loibl, G. von Minckwitz, N. Harbeck, W. Janni, D. Elling, M. Kaufmann, et al.
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
Breast Cancer Res, 10 (2008), pp. R77
[54.]
J.C. Gazet, H.T. Ford, R.C. Coombes, J.M. Bland, R. Sutcliffe, J. Quilliam, et al.
Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer.
Eur J Surg Oncol, 20 (1994), pp. 207-214
[55.]
I.S. Fentiman, M.R. Christiaens, R. Paridaens, A. van Geel, E. Rutgers, J. Berner, et al.
Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 Comparing tamoxifen alone with modified radical mastectomy.
Eur J Cancer, 39 (2003), pp. 309-316
[56.]
M. Fennessy, T. Bates, K. MacRae, D. Riley, J. Houghton, M. Baum, et al.
Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer.
Br J Surg, 91 (2004), pp. 699-704
[57.]
M.J. Ellis, C. Ma.
Letrozole in the neoadjuvant setting: the P024 trial.
Breast Cancer Res Treat, 105 (2007), pp. 33-43
[58.]
W. Eiermann, S. Paepke, J. Appfelstaedt, A. Llombart-Cussac, J. Eremin, J. Vinholes, et al.
Preoperative treatment of postmenopausal breast cancer patients with letrozole: randomized double-blind multicenter study.
Ann Oncol, 12 (2001), pp. 1527-1532
[59.]
De la Garza JG, Bargallo E, Solorio C, Ramírez T, Salazar F, Sánchez J. Multicentric study with neoadjuvant endocrine therapy for breast conserving surgery. Experience in Mexico; 2008 Dic 13; San Antonio: San Antonio Breast Cancer.
[60.]
I.E. Smith, M. Dowsett, S.R. Ebbs, J.M. Dixon, A. Skene, J.U. Blohmer, et al.
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
J Clin Oncol, 23 (2005), pp. 5108-5116
[61.]
L. Cataliotti, A.U. Buzdar, S. Noguchi, J. Bines, Y. Takatsuka, K. Petrakova, et al.
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) Trial.
Cancer, 106 (2006), pp. 2095-2103
[62.]
U. Krainick, A. Astner, W. Jonat, D. Wallwiener.
Phase II study to define safety and efficacy of exemestane as preoperative therapy for post menopausal patient with primary breast cancer-final results of the German Neoadjuvant Aromasin Initiative (GENARI).
Breast Cancer Rest Treat, 82 (2003), pp. S55
[63.]
V.V. Semiglazov, V.F. Semiglazov, G.A. Dashyan, E.K. Ziltsova, V.G. Ivanov, A.A. Bozhok, et al.
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer.
Cancer, 110 (2007), pp. 244-254
[64.]
H.J. Burstein, L.N. Harris, R. Gelman, S.C. Lester, R.A. Nunes, C.M. Kaelin, et al.
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ciclophosphamide for HER2 over expressing stage II or III breast cancer: pilod study.
Clin Oncol, 21 (2003), pp. 46-53
[65.]
J. Hurley, P. Dolini, I. Reis, O. Silva, C. Gómez-Fernández, P. Vélez, et al.
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal grow factor receptor 2-positive locally advanced breast cancer.
J Clin Oncol, 24 (2006), pp. 1831-1838
[66.]
A.U. Buzdar, N.K. Ibrahim, D. Francis, D.J. Booser, E.S. Thomas, R.L. Theriault, et al.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: results of a randomized trial in human epidermal grow factor receptor 2- positive operable breast cancer.
J Clin Oncol, 23 (2005), pp. 3676-3685
[67.]
B.P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, et al.
Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel and carboplatin for human epidermal grow factor receptor 2- over expressing stage II or III breast cancer: results of the GENT (A)-1 trial.
J Clin Oncol, 25 (2007), pp. 2678-2684
[68.]
R. Greil, M. Moik, R. Reitsamen, S. Ressler, M. Stoll, K. Namberger, et al.
Neoadjuvant, docetaxel and capecitabine combination therapy for HER2/neu negative invasive breast- cancer: Efficacy and safety in phase II pilot study.
EJSO, 35 (2009), pp. 1048-1054
[69.]
I. Makhoul, K.S. Vicki, S. Korourian, R.S. Henry-Tillman.
Bevacizumab combined with chemotherapy significantly improves pathologic complete response in patients with operable or locally advanced breast cancer.
SABCS, (2008),
[70.]
Y. Madarnas, M. Trudeau, J.A. Franek, D. McCready, K.I. Pritchard, H. Messersmith.
Adjuvant/neoadjuvant trastuzumab therapy in women with HER2/neu overexpressing breast cancer: a systematic review.
Cancer Treat Rev, 34 (2008), pp. 539-557
[71.]
W.R. Miller, J. Bartlett, A. Brodie, R.W. Brueggemeier, E. di Salle, P.E. Lønning, et al.
Aromatase Inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?.
The Oncologist, 13 (2008), pp. 829-837
Copyright © 2009. Instituto Nacional de Cancerología
Opciones de artículo
Herramientas
es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.